- Home
- ANL vs ORMP Comparison
ANL vs ORMP Comparison
Compare ANL & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- ORMP
- Stock Information
- Founded
- ANL 2004
- ORMP 2002
- Country
- ANL Cayman Islands
- ORMP United States
- Employees
- ANL N/A
- ORMP N/A
- Industry
- ANL
- ORMP Biotechnology: Pharmaceutical Preparations
- Sector
- ANL
- ORMP Health Care
- Exchange
- ANL Nasdaq
- ORMP Nasdaq
- Market Cap
- ANL 81.9M
- ORMP 84.3M
- IPO Year
- ANL 2023
- ORMP N/A
- Fundamental
- Price
- ANL $2.05
- ORMP $2.12
- Analyst Decision
- ANL Strong Buy
- ORMP Hold
- Analyst Count
- ANL 2
- ORMP 1
- Target Price
- ANL $9.00
- ORMP N/A
- AVG Volume (30 Days)
- ANL 6.8K
- ORMP 122.6K
- Earning Date
- ANL 04-08-2025
- ORMP 03-27-2025
- Dividend Yield
- ANL N/A
- ORMP N/A
- EPS Growth
- ANL N/A
- ORMP N/A
- EPS
- ANL N/A
- ORMP N/A
- Revenue
- ANL $5,000,000.00
- ORMP N/A
- Revenue This Year
- ANL N/A
- ORMP N/A
- Revenue Next Year
- ANL N/A
- ORMP N/A
- P/E Ratio
- ANL N/A
- ORMP N/A
- Revenue Growth
- ANL N/A
- ORMP N/A
- 52 Week Low
- ANL $1.85
- ORMP $1.96
- 52 Week High
- ANL $17.48
- ORMP $3.09
- Technical
- Relative Strength Index (RSI)
- ANL 38.59
- ORMP 37.34
- Support Level
- ANL $2.02
- ORMP $2.32
- Resistance Level
- ANL $2.49
- ORMP $2.40
- Average True Range (ATR)
- ANL 0.14
- ORMP 0.10
- MACD
- ANL -0.02
- ORMP -0.03
- Stochastic Oscillator
- ANL 7.22
- ORMP 7.41
Stock Price Comparison Chart: ANL vs ORMP
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About ORMP Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.